MKK4 status predicts survival after resection of gastric adenocarcinoma

Archives of Surgery

Volumn 141, Issue 11, 2006, Pages 1095-1099

  Cunningham, Steven C ^a,b   Kamangar, Farin ^a   Kim, Min P ^a,c   Hammoud, Sommer ^a   Haque, Raqeeb ^a   Iacobuzio Donahue, Christine ^a   Ashfaq, Raheela ^a   Kern, Scott E ^a   Maitra, Anirban ^a   Heitmiller, Richard E ^a,d   Choti, Michael A ^a   Lillemoe, Keith D ^a,e   Cameron, John L ^a   Yeo, Charles J ^a   Montgomery, Elizabeth ^a   Schulick, Richard D ^a,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNION MEMORIAL HOSPITAL   (United States)

^e INDIANA UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 4;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; GENE LOSS; HEALTH STATUS; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; STOMACH SURGERY; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; CHI-SQUARE DISTRIBUTION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE KINASE 4; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 33644762786     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.141.11.1095     Document Type: Article

References (18)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Teng DH, Perry WL III, Hogan JK, et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res. 1997;57:4177-4182.
3. Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res. 1998;58:2339-2342.
4. Su GH, Song JJ, Repasky EA, Schutte M, Kern SE. Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat. 2002;19:81-84.
5. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326-1331.
6. Fearon ER. Tumor-suppressor genes. In: Vogelstein B, Kinzler KW, eds. The Genetic Basis of Human Cancer. 2nd ed. New York, NY: McGraw-Hill; 2002:197-206.
7. Wang L, Pan Y, Dai JL. Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene. 2004;23:5978-5985.
8. Chae KS, Ryu BK, Lee MG, Byun DS, Chi SG. Expression and mutation analyses of MKK4, a candidate tumour suppressor gene encoded by chromosome 17p, in human gastric adenocarcinoma. Eur J Cancer. 2002;38:2048-2057.
9. Xin W, Yun KJ, Ricci F, et al. MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res. 2004;10:8516-8520.
10. Cunningham SC, Kamangar F, Kim MP, et al. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg. 2005;9:718-725.
11. Manley S, Mucci NR, De Marzo AM, Rubin MA. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. Am J Pathol. 2001;159:837-843.
12. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
13. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma; an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
14. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
15. Cunningham SC, Kamangar F, Kim MP, et al. Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol Biomarkers Prev. 2006;15:281-287.
16. Wu CW, Li AF, Chi CW, et al. Human gastric cancer kinase profile and prognostic significance of MKK4 kinase. Am J Pathol. 2000;156:2007-2015.
17. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327:293-297.
18. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.